Georgetown University

Akzo N.v.

Akzo Nobel N.v.

Per Immune Holdings, Inc.

Carl-Wilhelm Ernst Vogel

Reinhard Bredehorst

Nicholas Pomato

Richard P McCabe

David C Fritzinger

Chong-Ho Kim

Michael Kock

Gregory Alan Hawkins

Frances S Ligler

Thomas Grunwald

Anne W Kusterbeck

Gregory A Wemhoff

Gregory A Hawkins

Markus W Ollert

Richard D Wood

Jane J Zara

Patrick Ziegelmuller

Recombinant proCVF exhibits substantially the same activity as CVF and is useful for lowering complement activity.

Recombinant proCVF

Recombinant proCVF exhibits substantially the same activity as CVF and is useful for lowering complement activity

Recombinant procvf

A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog. Preferably, the affinity component is thermo-stabilized.

In vivo binding pair pretargeting

A method for in-vivo targeting a functional moiety in a patient by administering a targeting moiety coupled to an affinity component, wherein the targeting moiety has affinity for binding sites in a target area, and administering a binding partner to the affinity component coupled to a functional moiety to localize the functional moiety in the target area. Preferably the targeting moiety is an antibody and the functional moiety is a radiometal when performing in vivo imaging or therapy. The affinity component may be a novel methotrexate analog.

DNA sequences encoding cobra C3, CVF1, and CVF2, as well as plasmids and transformed hosts comprising such DNA sequences, are provided.

Cobra pro CVF1

A novel functionally active derivative of cobra venom factor is described in which the .beta.-chain has been cleaved by treatment with a protease. Gel electrophoretic analyses of the purified derivative revealed the absence of an intact .beta.-chain and a decrease of the molecular weight.

Protease-derivatized CVF

A method for site-specific in-vivo activation of a prodrug in an animal using an activator-targeting moiety conjugate to localize an activator at a predetermined site of use and a prodrug compound that is converted to an active drug in the presence of the activator. In the preferred embodiment, the targeting moiety, the activator, and the prodrug demonstrate little or no immunogenicity in the animal being treated. The targeting moiety is relatively specific for binding to the target tissue than to non-target tissue. The activator is not found or present in only small amounts in circulation or in non-target tissue, does not have a substrate for its activity in circulation or in non-target tissue, can be linked to the targeting moiety, and is capable of converting the prodrug to an active drug. The prodrug is selected for its ability to exert a cytotoxic activity on the target tissue after conversion by the activator.

Site specific in vivo activation of therapeutic drugs

Site-specific heterobifunctional crosslinkers of the formula:

S-(2-thiopyridyl)-L-cysteine, a heterobifunctional crosslinking reagent

Ligand-label conjugates which are an oligopeptide of 5 to 100 amino acid residues, bonded to a ligand or receptor, which contain a plurality of chemiluminescent or fluorescent labels and a plurality of polyoxoanions of sulfur or phosphorus are useful for immunoassays. Such conjugates are hydrophilic and exhibit very low nonspecific binding, thereby significantly increasing the signal to background ratio in immunoassays.

Growing community of inventors

Hamburg, Germany

Carl-Wilhelm Ernst Vogel